Top

Published in:

01-04-2014 | Original Article

Radiological features of supratentorial gliomas are associated with their genetic aberrations

Authors: Yuya Nishiyama, Hikaru Sasaki, Shinya Nagahisa, Kazihide Adachi, Takuro Hayashi, Koichiro Yoshida, Tsukasa Kawase, Natsuki Hattori, Kazuhiro Murayama, Masato Abe, Mitsuhiro Hasegawa, Yuichi Hirose

Published in: Neurosurgical Review | Issue 2/2014

Excerpt

Gliomas are the most common primary neoplasms of the central nervous system [1]. Histopathological examination of surgically resected tissue is essential for the diagnosis of gliomas, and it forms the basis on which decisions regarding the use of adjuvant therapies are taken. This methodology has several potential difficulties, however. These include the fact that even pathologically identical tumors may have a different prognosis, that occasionally different areas of the same tumor tissue can have different histological characteristics [2], and that there is no entirely objective way of interpreting cellularity, anaplasia, or even cell type. To address these problems, many studies have tried to distinguish tumors on the basis of genetic and protein markers with the aim of standardizing decisions regarding therapeutic strategy based on the tumor subtypes they defined [3, 4]. Of particular note are the allelic losses of chromosomes 1p and 19q (−1p/19q), which have been reported as being positive predictors of chemotherapeutic response for anaplastic oligodendroglial tumors [5, 6]. Moreover, after Parsons et al. demonstrated that some gliomas carry a mutation in the IDH1 gene, genetic investigations have become increasingly important in the study of glioma biology [7]. However, although genetic analysis does provide important information, it requires an invasive surgical procedure. …

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109PubMedCentralPubMedCrossRef

Aldape K, Simmons ML, Davis RL, Miike R, Wiencke J, Barger G, Lee M, Chen P, Wrensch M (2000) Discrepancies in diagnoses of neuroepithelial neoplasms. Cancer 88:2342–2349PubMedCrossRef

Nagarajan RP, Costello JF (2009) Molecular epigenetics and genetics in neuro-oncology. Neurotherapeutics 6:436–446PubMedCrossRef

Wrensch M, Fisher JL, Schwartzbaum JA, Bondy M, Berger M, Aldape KD (2005) The molecular epidemiology of gliomas in adults. Neurosurg Focus 19:1–11CrossRef

Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, Fulton D, Dropcho E, Stewart D, Schold C, Wainman N, Eisenhauer E (1994) Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12:2013PubMed

van den Bent MJ, Kros JM, Heimans JJ, Pronk LC, van Groeningen CJ, Krouwer HG, Taphoorn MJ, Zonnenberg BA, Tijssen CC, Twijnstra A, Punt CJ, Boogerd W (1998) Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 51:1140–1145PubMedCrossRef

Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807–1812PubMedCentralPubMedCrossRef

Kleihues P, Cavenee WK (eds) (2000) World Health Organization classification of tumors of the nervous system. IARC/WHO, Lyon

Hirose Y, Aldape K, Takahashi M, Berger MS, Feuerstein BG (2001) Tissue micro- dissection and degenerate oligonucleotide primed polymerase chain reaction (DOP-PCR) is an effective method to analyze genetic aberrations in invasive tumors. J Mol Diagn 3(2):62–67PubMedCentralPubMedCrossRef

10.

Mohapatra G, Moore DH, Kim DH, Grewal L, Hyun WC, Waldman FM, Pinkel D, Fueuerstein BG (1997) Analyses of brain tumor cell lines confirm a simple model of relationships among fluorescence in situ hybridization, DNA index, and comparative genomic hybridization. Genes Chromosom Cancer 20:311–319PubMedCrossRef

11.

Watanabe T, Nobusawa S, Kleinhues P, Ohgaki H (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174:n1149–n1153CrossRef

12.

Jenkinson MD, du Plessis DG, Smith TS, Joyce KA, Warnke PC, Walker C (2006) Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain 129:1884–1891PubMedCrossRef

13.

Megyesi JF, Kachur E, Lee DH, Zlatescu MC, Betensky RA, Forsyth PA, Okada Y, Sasaki H, Mizoguchi M, Louis DN, Cairncross JG (2004) Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res 10:4303–4306PubMedCrossRef

14.

Cairncross G, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90(19):1473–1479. doi:10.1093/jnci/90.19.1473 PubMedCrossRef

15.

Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707–2714. doi:10.1200/JCO.2005.04.3414 PubMedCrossRef

16.

van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma- Reiche H, Kros JM, van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D, Gorlia T (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diag- nosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European organisation for research and treatment of cancer phase III trial. J Clin Oncol 24:2715–2722. doi:10.1200/JCO.2005.04.6078 PubMedCrossRef

17.

Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M, Flynn H, Passe S, Felten S, Brown PD, Shaw EG, Buckner JC (2006) A t (1; 19)(q10; p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66:9852–9861. doi:10.1158/0008-5472. CAN-06-1796 PubMedCrossRef

18.

Arslantas A, Artan S, Oner U, Müslümanoğlu H, Durmaz R, Cosan E, Atasoy MA, Basaran N, Tel E (2004) The importance of genomic copy number changes in the prognosis of glioblastoma multiforme. Neurosurg Rev 27:58–64PubMedCrossRef

19.

Hirose Y, Aldape K, Bollen A, James CD, Brat D, Lamborn K, Berger M, Feuerstein BG (2001) Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups. Am J Pathol 158(3):1137–1143PubMedCentralPubMedCrossRef

20.

Hirose Y, Aldape KD, Chang S, Lamborn K, Berger MS, Feuerstein BG (2003) Grade II astrocytomas are subgrouped by chromosome aberrations. Cancer Genet Cytogenet 142(1):1–7. doi:10.1016/S0165-4608(02)00791-4 PubMedCrossRef

21.

Hirose Y, Sasaki H, Miwa T, Ohba S, Ikeda E, Abe M, Ikeda S, Kobayashi M, Kawase T, Hasegawa M, Yoshida K (2011) Whole genome analysis from microdissected tissue revealed adult supratentorial grade II–III gliomas are divided into clinically relevant subgroups by genetic profile. Neurosurgery 69(2):376–390PubMedCrossRef

22.

Kunwar S, Mohapatra G, Bollen A, Lamborn KR, Prados M, Feuerstein BG (2001) Genetic subgroups of anaplastic astrocytomas correlate with patient age and survival. Cancer Res 61:7683–7688PubMed

23.

Kraus JA, Koopmann J, Kaskel P, Maintz D, Brandner S, Schramm J, Louis DN, Wiestler OD, von Deimling A (1995) Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 54:91–95PubMedCrossRef

24.

Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J, Veelken J, Schramm J, Weller M, Weistler OD, Louis DN, von Deimling A (2002) Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 161(1):313–319PubMedCentralPubMedCrossRef

25.

Smith JS, Alderete B, Minn Y, Borell TJ, Perry A, Mohapatra G, Hosek SM, Kimmel D, O'Fallon J, Yates A, Feuerstein BG, Burger PC, Scheithauer BW, Jenkins R (1999) Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 18:4144–4152PubMedCrossRef

26.

Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636–645PubMed

27.

Choi C, Ganji SK, DeBerardinis RJ, Hatanpaa KJ, Rakheja D, Kovacs Z, Yang XL, Mashimo T, Raisanen JM, Marin-Valencia I, Pascual JM, Madden CJ, Mickey BE, Malloy CR, Bachoo RM, Maher EA (2012) 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 18(4):624–629PubMedCentralPubMedCrossRef

28.

Daumas-Duport C, Varlet P, Tucker ML, Beuvon F, Cervera P, Chodkiewicz JP (1997) Oligodendrogliomas. Part I: patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases. J Neuro-Oncol 34:37–59CrossRef

29.

Kim JW, Park CK, Park SH, Kim YH, Han JH, Kim CY, Sohn CH, Chang KH, Jung HW (2011) Relationship between radiological characteristics and combined 1p and 19q deletion in World Health Organization grade III oligodendroglial tumours. J Neurol Neurosurg Psychiatry 82(2):224–227PubMedCrossRef

30.

Koeller KK, Rushing EJ (2005) From the archives of the AFIP: oligodendroglioma and its variants: radiologic–pathologic correlation. Radiographics 25:1669–1688PubMedCrossRef

31.

Laigle-Donadey F, Martin-Duverneuil N, Lejeune J, Crinière E, Capelle L, Duffau H, Cornu P, Broet P, Kujas M, Mokhtari K, Carpentier A, Sanson M, Hoang-Xuan K, Thillet J, Dlattre JY (2004) Correlations between molecular profile and radiologic pattern in oligodendroglial tumors. Neurology 63:2360–2362PubMedCrossRef

32.

Sherman JH, Prevedello DM, Shah L, Raghavan P, Pouratian N, Starke RM, Lopes MB, Shaffrey ME, Schiff D (2010) MR imaging characteristics of oligodendroglial tumors with assessment of 1p/19q deletion status. Acta Neurochir (Wien) 152(11):1827–1834CrossRef

33.

Talos IF, Zou KH, Ohno-Machado L, Bhagwat JG, Kikinis R, Black PM, Jolesz FA (2006) Supratentorial low-grade glioma resectability: statistical predictive analysis based on anatomic MR features and tumor characteristics. Radiology 239:506–513PubMedCentralPubMedCrossRef

34.

Zlatescu MC, TehraniYazdi A, Sasaki H, Megyesi JF, Betensky RA, Louis DN, Cairncross JG (2001) Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res 61(18):6713–6715PubMed

35.

Sanai N, Alvarez-Buylla A, Berger MS (2005) Neural stem cells and the origin of gliomas. N Engl J Med 353(8):811–822PubMedCrossRef

36.

Vergani F, Martino J, Gozé C, Rigau V, Duffau H (2011) World Health Organization grade II gliomas and subventricular zone: anatomic, genetic, and clinical considerations. Neurosurgery 68(5):1293–1298PubMed

37.

Duffau H, Capelle L (2004) Preferential brain locations of low-grade gliomas. Cancer 100(12):2622–2626PubMedCrossRef

38.

van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 6(5):421–430PubMedCrossRef

39.

Anja S, Hugues D (2011) Seizures and the natural history of World Health Organization grade II gliomas: a review. Neurosurgery 68:1326–1333. doi:10.1227/NEU.0b013e31820c3419

40.

Vogelbaum MA, Berkey B, Peereboom D, Macdonald D, Giannini C, Suh JH, Jenkins R, Herman J, Brown P, Blumenthal DT, Boggs C, Schltz C, Mehta M (2009) Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed oligoastrocytomas : RTOG BR0131. Neuro Oncol 11(2):167–175PubMedCentralPubMedCrossRef

41.

Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, Lejeune J, Polivka M, Crinière E, Marie Y, Mokhtari K, Carpentier AF, Laigle F, Simon JM, Cornu P, Broët P, Sanson M, Delattre JY (2004) Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 22(15):3133–3138PubMedCrossRef

Title: Radiological features of supratentorial gliomas are associated with their genetic aberrations
Authors: Yuya Nishiyama
Hikaru Sasaki
Shinya Nagahisa
Kazihide Adachi
Takuro Hayashi
Koichiro Yoshida
Tsukasa Kawase
Natsuki Hattori
Kazuhiro Murayama
Masato Abe
Mitsuhiro Hasegawa
Yuichi Hirose
Publication date: 01-04-2014
Publisher: Springer Berlin Heidelberg
Published in: Neurosurgical Review / Issue 2/2014
Print ISSN: 0344-5607
Electronic ISSN: 1437-2320
DOI: https://doi.org/10.1007/s10143-013-0515-5

At a glance: The STEP trials

Springer Medicine

Radiological features of supratentorial gliomas are associated with their genetic aberrations

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2014

Traumatic injuries to the craniovertebral junction: a review of rare events

Imaging changes following stereotactic radiosurgery for metastatic intracranial tumors: differentiating pseudoprogression from tumor progression and its effect on clinical practice

Surgical management of ocular symptoms in spheno-orbital meningiomas. Is orbital reconstruction really necessary?

Endoscopic endonasal approach in the management of skull base chordomas—clinical experience on a large series, technique, outcome, and pitfalls

Pathophysiology and management of intracranial arterial stenosis around the circle of Willis associated with hyperthyroidism: case reports and literature review

Endoscopic transchoroidal and transforaminal approaches for resection of third ventricular colloid cysts